GLPwatch
Papers (10373)
Page 27 of 173, ranked by citation count.
- Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice.
- GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-κB signalling pathway.
- Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.
- Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation.
- No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial.
- GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
- Oral semaglutide in type 2 diabetes.
- Mild renal impairment and the efficacy and safety of liraglutide.
- Amylin as a Future Obesity Treatment.
- Large-molecule quantification: sensitivity and selectivity head-to-head comparison of triple quadrupole with Q-TOF.
- Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics.
- Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
- Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity.
- Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.
- The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution.
- Effect of liraglutide on expression of inflammatory genes in type 2 diabetes.
- Effect of GLP-1 Receptor Activation on Offspring Kidney Health in a Rat Model of Maternal Obesity.
- Exendin-4 inhibits structural remodeling and improves Ca<sup>2+</sup> homeostasis in rats with heart failure via the GLP-1 receptor through the eNOS/cGMP/PKG pathway.
- Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K/Akt/GSK-3β pathway.
- Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
- Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding-associated neuropeptides in hypothalamic neurons in vivo and in vitro.
- Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.
- GLP-1 receptor agonists and heart failure in diabetes.
- The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
- Recent advances in incretin-based therapies.
- A comparison of preferences for two GLP-1 products--liraglutide and exenatide--for the treatment of type 2 diabetes.
- Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.
- The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis.
- Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis.
- Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor.
- Longitudinal Analysis of Obesity Drug Use and Public Awareness.
- Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets.
- Exendin-4 ameliorates high glucose-induced fibrosis by inhibiting the secretion of miR-192 from injured renal tubular epithelial cells.
- Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults.
- FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management.
- Differentiation of human adipose-derived mesenchymal stem cell into insulin-producing cells: an in vitro study.
- The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide.
- Exendin-4 promotes proliferation and differentiation of MC3T3-E1 osteoblasts by MAPKs activation.
- Protective action of liraglutide in beta cells under lipotoxic stress via PI3K/Akt/FoxO1 pathway.
- FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade.
- Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.
- The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.
- One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice.
- Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
- Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
- Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
- Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms.
- In Vitro Platform for Studying Human Insulin Release Dynamics of Single Pancreatic Islet Microtissues at High Resolution.
- Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1.
- Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial.
- Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury.
- Interventions for Weight Management in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
- Pediatric obesity pharmacotherapy: current state of the field, review of the literature and clinical trial considerations.
- Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing.
- The therapeutic potential of GLP-1 analogues for stress-related eating and role of GLP-1 in stress, emotion and mood: a review.
- Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer's Disease: A Systematic Review.
- Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review.
- Tirzepatide and prevention of chronic kidney disease.
- Creating the amylin story.
- Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.